PNC Financial Services Group Inc. lowered its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 1.7% in the first quarter, HoldingsChannel.com reports. The fund owned 57,764 shares of the life sciences company’s stock after selling 972 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Integra Lifesciences were worth $3,217,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of IART. Quadrant Capital Group LLC lifted its position in Integra Lifesciences by 223.0% in the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after buying an additional 446 shares in the last quarter. Enlightenment Research LLC bought a new position in shares of Integra Lifesciences during the 4th quarter valued at $32,000. Fort L.P. bought a new position in shares of Integra Lifesciences during the 4th quarter valued at $34,000. Executive Wealth Management LLC bought a new position in shares of Integra Lifesciences during the 4th quarter valued at $38,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock valued at $129,000 after purchasing an additional 1,266 shares in the last quarter. Institutional investors own 82.27% of the company’s stock.

NASDAQ:IART traded up $0.11 during midday trading on Wednesday, reaching $49.82. The stock had a trading volume of 3,002 shares, compared to its average volume of 473,274. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $67.50. The company has a current ratio of 2.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $4.26 billion, a PE ratio of 20.60, a PEG ratio of 1.43 and a beta of 0.97.

Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The business had revenue of $359.69 million for the quarter, compared to analyst estimates of $361.12 million. During the same period last year, the business posted $0.58 EPS. Integra Lifesciences’s revenue was up .7% compared to the same quarter last year. As a group, analysts anticipate that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current fiscal year.

IART has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Tuesday, April 23rd. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a report on Tuesday, March 19th. JMP Securities restated a “buy” rating and set a $62.00 price target on shares of Integra Lifesciences in a report on Wednesday, February 27th. Morgan Stanley set a $57.00 price target on shares of Integra Lifesciences and gave the company a “hold” rating in a report on Friday, February 22nd. Finally, Cantor Fitzgerald restated a “hold” rating and set a $50.00 price target on shares of Integra Lifesciences in a report on Thursday, February 21st. Three analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $58.00.

In other Integra Lifesciences news, insider Lisa Evoli sold 1,291 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $55.90, for a total value of $72,166.90. Following the sale, the insider now directly owns 4,968 shares in the company, valued at approximately $277,711.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rhonda Germany Ballintyn purchased 1,933 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was bought at an average price of $56.08 per share, for a total transaction of $108,402.64. Following the completion of the transaction, the director now directly owns 3,665 shares in the company, valued at $205,533.20. The disclosure for this purchase can be found here. Company insiders own 4.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Integra Lifesciences Holdings Corp (NASDAQ:IART) Position Cut by PNC Financial Services Group Inc.” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://theolympiareport.com/2019/06/12/integra-lifesciences-holdings-corp-nasdaqiart-position-cut-by-pnc-financial-services-group-inc.html.

Integra Lifesciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: CD Ladder

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.